Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
Tomomi Nakamura1, Chiho Nakashima1, Kazutoshi Komiya1
1Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine, Saga University, Saga, Japan.
Abstract:
Although mechanisms of acquired resistance to 1st and 3rd generation EGFR-TKI continue to be elucidated, there have been few clinical investigations into the mechanisms of acquired resistance to the 2nd generation EGFR-TKI afatinib. We analyzed data from 20 patients with advanced lung adenocarcinoma who acquired resistance to afatinib, including resistance during EGFR-TKI re-challenge. We examined EGFR T790M and C797S mutations, BRAF V600E mutation, and MET amplification with the MBP-QP method and with droplet digital PCR using ctDNA and re-biopsy samples obtained before and after afatinib treatment. Just before afatinib treatment, 15 of the 20 patients were T790M negative and five were positive. Among the T790M negative patients, 40.0% (6/15) became positive at the time of PD under afatinib. In patients positive for T790M, changes in T790M allele frequency were correlated with afatinib treatment efficacy. C797S was not detected in any patients just before afatinib treatment, but it appeared after treatment in three patients, although with very low allele frequency. Two of these three patients, although positive for both C797S and T790M, achieved PR to osimertinib. However, PFS of these patients was somewhat shorter than that of patients positive for T790M only. BRAF V600E was detected in one patient at PD under afatinib. MET amplification was not detected in this study. T790M is associated with acquired resistance to afatinib, as with 1st generation EGFR-TKI, but with somewhat lower frequency. The influence of C797S on resistance to afatinib is less than that of T790M, but C797S might cause shorter PFS under osimertinib.
Insights
Acquired resistance to afatinib in lung cancer is often linked to EGFR T790M mutations. The C797S mutation also appears post-treatment, potentially impacting progression-free survival with subsequent therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are crucial for optimizing lung cancer treatment.
- While resistance to 1st and 3rd generation EGFR-TKIs is well-studied, investigations into resistance to the 2nd generation EGFR-TKI afatinib are limited.
Purpose of the Study:
- To investigate the molecular mechanisms of acquired resistance to afatinib in patients with advanced lung adenocarcinoma.
- To analyze the prevalence and impact of key resistance mutations, including EGFR T790M and C797S, BRAF V600E, and MET amplification.
Main Methods:
- Analysis of clinical data from 20 patients with advanced lung adenocarcinoma who developed resistance to afatinib.
- Detection of EGFR T790M, C797S, BRAF V600E mutations, and MET amplification using MBP-QP and droplet digital PCR on ctDNA and re-biopsy samples.
- Assessment of mutation status before and after afatinib treatment.
Main Results:
- EGFR T790M mutation was associated with acquired resistance to afatinib, detected in 40% of initially T790M-negative patients at progression.
- Changes in T790M allele frequency correlated with afatinib treatment efficacy.
- C797S mutation appeared post-treatment in three patients, with two achieving partial response to osimertinib, but exhibiting shorter progression-free survival compared to T790M-only patients.
- BRAF V600E was detected in one patient; MET amplification was not observed.
Conclusions:
- EGFR T790M is a significant mechanism of acquired resistance to afatinib, similar to 1st generation EGFR-TKIs, though observed at a lower frequency.
- The C797S mutation, while less frequent, may influence resistance to afatinib and potentially lead to shorter progression-free survival under osimertinib treatment.
- Further research is needed to fully elucidate the role of C797S in afatinib resistance and subsequent treatment outcomes.
More Related Videos
05:26A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
Published on: September 16, 2022
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Resistivity
Resistance
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Rolling Resistance
For instance, imagine a hard cylinder rolling on a comparatively soft surface. The cylinder's weight compresses the surface beneath it. As the cylinder moves, the material in front of it slows down due to...
Vascular Resistance
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
